Sensitivity of squamous cell carcinoma lymph node metastases to herpes oncolytic therapy

Clinical Cancer Research

Volumn 14, Issue 6, 2008, Pages 1897-1904

  Yu, Zhenkun ^a,b   Li, Sen ^a   Huang, Yu Yao ^a,c   Lin, Shu Fu ^a,c   Fong, Yuman ^a   Wong, Richard J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CELL SURFACE PROTEIN; GLYCOPROTEIN D; HERPES SIMPLEX VIRUS 1 RECEPTOR; NECTIN 1; NV 1023; UNCLASSIFIED DRUG; VIRUS RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL MIGRATION; CONTROLLED STUDY; CYTOTOXICITY; DISEASE MODEL; FEMALE; GENE EXPRESSION; GENE THERAPY; HERPES SIMPLEX; IN VITRO STUDY; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN BINDING; SQUAMOUS CELL CARCINOMA; TUMOR REGRESSION; VIRUS ENTRY; VIRUS REPLICATION;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; HERPESVIRUS 1, HUMAN; LYMPHATIC METASTASIS; MICE; MICE, INBRED C3H; NEOPLASM INVASIVENESS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROTEIN BINDING; SKIN NEOPLASMS; VIRAL ENVELOPE PROTEINS; VIRUS INTERNALIZATION;

EID: 41549111171     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4615     Document Type: Article

References (24)

1. Minn AJ, Kang Y, Serganova I, et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Investig 2005;115:44-55.
2. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995;1:938-43.
3. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 1998;9:2177-85.
4. Kooby D, Carew JF, Halterman MW, et al. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 1999;13:1325-34.
5. Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RL. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 1999;10:2237-43.
6. Wong RJ, Kim SH, Joe JK, Shah JP, Johnson PA, Fong Y. Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg 2001;193:12-21.
7. Yu Z, Eisenberg DP, Singh B, Shah JP, Fong Y, Wong RJ. Treatment of aggressive thyroid cancer with an oncolytic herpes virus. Int J Cancer 2004;112:525-32.
8. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000;7:867-74.
9. Rampling R, Cruickshank G, Papanastassiou V, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000;7:859-66.
10. Kemeny N, Brown K, Covey A, et al. Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 2006;17:1214-24.
11. Wong RJ, Patel SG, Kim SH, et al. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther 2001;12:253-65.
12. Stanziale SF, Stiles BM, Bhargava A, Kerns SA, Kalakonda N, Fong Y. Oncolytic herpes simplex virus-1 mutant expressing green fluorescent protein can detect and treat peritoneal cancer. Hum Gene Ther 2004;15:609-18.
13. Wong RJ, Chan MK, Yu, Z, et al. Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res 2004;10:251-9.
14. Wong RJ, Joe JK, Kim SH, Shah JP, Horsburgh B, Fong Y. Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to sites of lymphatic metastases. Hum Gene Ther 2002;13:1213-23.
15. Eisenberg DP, Adusumilli PS, Hendershott KJ, et al. Real-time intraoperative detection of breast cancer axillary lymph node metastases using a green fluorescent protein-expressing herpes virus. Ann Surg 2006;243:824-30.
16. Yu Z, Adusumilli PS, Eisenberg DP, et al. Nectin-1 expression by squamous cell carcinoma is a predictor of herpes oncolytic sensitivity. Mol Ther 2007;15:103-13.
17. Yu Z, Chan MK, O-charoenrat P, et al. Enhanced nectin-1 expression and herpes oncolytic sensitivity in highly migratory and invasive carcinoma. Clin Cancer Res 2005;11:4889-97.
18. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988;158:602-14.
19. Spear PG, Longnecker R. Herpesvirus entry: an update. J Virol 2003;77:10179-85.
20. Yu Z, Li S, Huang YY, Fong Y, Wong RJ. Calcium depletion enhances nectin-1 expression and herpes oncolytic therapy of squamous cell carcinoma. Cancer Gene Ther 2007;14:738-47.
21. Shah JP. Head and neck surgery, 2nd Ed. London: Mosby-Wolfe;1996. p. 355.
22. Clayman GL, el-Naggar AK, Lippman SM, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998;16:2221-32.
23. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001;19:289-98.
24. Beavon IR. The e-cadherin-catenin complex in tumour metastasis: structure, function, and regulation. Eur J Cancer 2000;36:1607-20.